deltatrials
Completed PHASE3 NCT00140075

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer

Sponsor: Pfizer

Conditions Adenocarcinoma
Interventions Epirubicin with Cyclophosphamide, followed by a Taxane Epirubicin with a Taxane
Updated 7 times since 2017 Last updated: May 24, 2011 Started: Nov 30, 2000 Primary completion: Aug 31, 2006 Completion: Aug 31, 2006

Listed as NCT00140075, this PHASE3 trial focuses on Adenocarcinoma and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Arlington, United States, Atlanta, United States, Bakersfield, United States, Baltimore, United States, Baton Rouge, United States, Belleville, United States, Berkeley, United States, Boston, United States, Brooklyn, United States and 42 more location s